Fulvestrant en la práctica clínica: análisis de efectividad en pacientes uruguayas con cáncer de mama HR+/HER2.

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL
Natalia Camejo, Dahiana Amarillo, Cecilia Castillo, Sofía Badía Alza, Camila Baliño, Miguel Banchieri, Juan Fagundez, Santiago Ghiga, Marcos Lorier, Isabel Alonso, Gabriel David Krygier Waltier
{"title":"Fulvestrant en la práctica clínica: análisis de efectividad en pacientes uruguayas con cáncer de mama HR+/HER2.","authors":"Natalia Camejo, Dahiana Amarillo, Cecilia Castillo, Sofía Badía Alza, Camila Baliño, Miguel Banchieri, Juan Fagundez, Santiago Ghiga, Marcos Lorier, Isabel Alonso, Gabriel David Krygier Waltier","doi":"10.5867/medwave.2024.08.2923","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies.</p><p><strong>Methods: </strong>A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test.</p><p><strong>Results: </strong>A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival.</p><p><strong>Conclusions: </strong>Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research.</p>","PeriodicalId":18597,"journal":{"name":"Medwave","volume":"24 8","pages":"e2923"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medwave","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5867/medwave.2024.08.2923","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies.

Methods: A database from the National Resources Fund covering the period from 2009 to 2022 was used. Survival curves were assessed using the Kaplan-Meier method, and differences were analyzed using the Log-Rank test.

Results: A total of 1085 patients with an average age of 63,66 years were included. Following a follow-up of 14 months, the median overall survival was 16 months, and the median progression-free survival was 6 months. The presence of liver and bone metastases was associated with a shorter overall survival. Patients from the public sector and those with a better performance status experienced longer overall survival.

Conclusions: Our findings provide a valuable perspective for treatment management in a context of limited resources. Overall survival and progression-free survival were somewhat lower than those reported in pivotal clinical trials. The presence of liver and bone metastases was associated with worse prognosis and survival; additionally, patients with worse performance status had shorter overall survival. These findings underscore the need for personalized therapies, opening new lines of future research.

氟维司群在临床实践中的应用:对乌拉圭 HR+/HER2 乳腺癌患者的疗效分析。
简介氟维司群对激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者的总生存期和无进展生存期均有益处。为了了解氟维司群在常规临床实践中的疗效,并将我们的结果与关键性研究的结果进行比较,我们根据国家资源基金的国家治疗覆盖方案,对接受氟维司群治疗的激素受体阳性、HER2阴性乳腺癌患者的特征、演变和生存情况进行了评估:方法:使用国家资源基金2009年至2022年期间的数据库。采用Kaplan-Meier法评估生存曲线,并用Log-Rank检验分析差异:结果:共纳入 1085 名患者,平均年龄为 63.66 岁。随访14个月后,中位总生存期为16个月,中位无进展生存期为6个月。肝转移和骨转移与总生存期缩短有关。来自公共部门和表现较好的患者总生存期较长:我们的研究结果为在资源有限的情况下进行治疗管理提供了有价值的视角。总生存期和无进展生存期略低于关键临床试验的报告。肝转移和骨转移与较差的预后和生存率有关;此外,表现较差的患者总生存期较短。这些发现强调了个性化疗法的必要性,为今后的研究开辟了新的思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medwave
Medwave MEDICINE, GENERAL & INTERNAL-
CiteScore
2.60
自引率
8.30%
发文量
50
审稿时长
12 weeks
期刊介绍: Medwave is a peer-reviewed, biomedical and public health journal. Since its foundation in 2001 (Volume 1) it has always been an online only, open access publication that does not charge subscription or reader fees. Since January 2011 (Volume 11, Number 1), all articles are peer-reviewed. Without losing sight of the importance of evidence-based approach and methodological soundness, the journal accepts for publication articles that focus on providing updates for clinical practice, review and analysis articles on topics such as ethics, public health and health policy; clinical, social and economic health determinants; clinical and health research findings from all of the major disciplines of medicine, medical science and public health. The journal does not publish basic science manuscripts or experiments conducted on animals. Until March 2013, Medwave was publishing 11-12 numbers a year. Each issue would be posted on the homepage on day 1 of each month, except for Chile’s summer holiday when the issue would cover two months. Starting from April 2013, Medwave adopted the continuous mode of publication, which means that the copyedited accepted articles are posted on the journal’s homepage as they are ready. They are then collated in the respective issue and included in the Past Issues section.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信